

MERRIMACK PHARMACEUTICALS INC  
Form 8-K  
March 30, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 30, 2017**

**Merrimack Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

<b>Delaware</b> <b>(State or Other Juris-</b>	<b>001-35409</b> <b>(Commission</b>	<b>04-3210530</b> <b>(IRS Employer</b>
<b>diction of Incorporation</b>	<b>File Number)</b>	<b>Identification No.)</b>

**One Kendall Square, Suite B7201**

<b>Cambridge, MA</b> <b>(Address of Principal Executive Offices)</b>	<b>02139</b> <b>(Zip Code)</b>
<b>Registrant's telephone number, including area code: (617) 441-1000</b>	

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

At the Special Meeting of Stockholders of Merrimack Pharmaceuticals, Inc. (the Company) held on March 30, 2017, the Company's stockholders voted as follows:

1. The stockholders approved the Asset Sale pursuant to the terms of the Asset Purchase and Sale Agreement, dated January 7, 2017, by and between the Company and Ipsen S.A.

For:	80,257,918
Against:	2,280,140
Abstain:	310,077

2. The stockholders approved adoption of any proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to approve the Asset Sale at the time of the Special Meeting.

For:	74,415,285
Against:	8,034,695
Abstain:	398,155

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERRIMACK PHARMACEUTICALS, INC.

Date: March 30, 2017

By: /s/ Jeffrey A. Munsie  
Jeffrey A. Munsie

General Counsel